FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Federal regulators have mandated new warning labels regarding a rare risk of permanent vision loss and sudden blindness across the entire class of GLP-1 receptor agonist medications. The safety action applies to widely used diabetes and weight-loss treatments including Ozempic, Wegovy, Mounjaro, and Zepbound. The updated product labeling highlights the potential danger of developing non-arteritic anterior ischemic optic neuropathy, a serious eye condition. Users have previously filed lawsuits alleging they developed the vision-damaging condition after taking these popular therapies.
Listen to Live Briefing
Real-time synthesized voice briefing ยท Live Feeds Desk
- โ The FDA ordered new warning labels on GLP-1 drugs over the rare risk of permanent vision loss and sudden blindness.
- โ The warning applies to medications including Ozempic, Wegovy, Mounjaro, and Zepbound.
- โ The regulatory action addresses non-arteritic anterior ischemic optic neuropathy.
- โ Users have filed lawsuits alleging they developed the rare eye condition after taking drugs such as Ozempic and Wegovy.
What changed
The Food and Drug Administration officially ordered manufacturers to add warnings for the rare eye condition across all GLP-1 receptor agonist drugs.
Live updates
-
FDA Orders Vision Loss Warnings for GLP-1 Drugs
Federal regulators have mandated new warning labels regarding a rare risk of permanent vision loss and sudden blindness across the entire class of GLP-1 receptor agonist medications. The safety action applies to widely used diabetes and weight-loss treatments including Ozempic, Wegovy, Mounjaro, and Zepbound. The updated product labeling highlights the potential danger of developing non-arteritic anterior ischemic optic neuropathy, a serious eye condition. Users have previously filed lawsuits alleging they developed the vision-damaging condition after taking these popular therapies.
Why it matters
The federal intervention addresses growing safety concerns surrounding medications that have surged in global popularity for managing both type 2 diabetes and obesity. Regulatory authorities are stepping in as legal challenges accumulate from patients reporting severe ocular side effects. Updating the class-wide labeling aims to ensure that physicians and patients are explicitly aware of the rare optic complication before initiating treatment.
What is confirmed
- The FDA ordered new warning labels on GLP-1 drugs over the rare risk of permanent vision loss and sudden blindness.
- The warning applies to medications including Ozempic, Wegovy, Mounjaro, and Zepbound.
- The regulatory action addresses non-arteritic anterior ischemic optic neuropathy.
- Users have filed lawsuits alleging they developed the rare eye condition after taking drugs such as Ozempic and Wegovy.
What to watch next
- Manufacturer updates to official product labeling and medication guides
- Further legal filings and court developments in patient lawsuits against drug makers
confidence 95%Sources used for this update (18)
- www.cnn.com โ Breaking News, Latest News and Videos | CNN
- www.goodmorningamerica.com โ GMA - Good Morning America
- www.nbcnews.com โ NBC News - Breaking Headlines and Video Reports on World, U.S....
- abcnews.com โ ABC News - Breaking News, Latest News and Videos
- www.foxbusiness.com โ Great Business Leaders in America & Around the World | Fox Business
- www.thenationalnews.com โ Arab Israelis wake to new political dawn after record election success
- www.mogazmasr.com โ Nelson Peltz's Trian offers $1.4 billion for Wendy's as shares jump
- CNN โ US FDA orders new eye risk warnings for Ozempic, Zepbound
- NBC News โ FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
- www.inquisitr.com โ Shrapnel damages Saudi Aramco building in Riyadh
- WSJ โ U.S. Regulators Warn GLP-1 Drugs Carry Possible Rare Blindness Risk
- CNBC โ FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
Community Sentiment: How do you assess this situation?
Voice your perspective ยท Real-time aggregated sentiment from the Live Feeds community